Drug Type Small molecule drug |
Synonyms (+)-ampelopsin, (+)-dihydromyricetin, Ampelopsin + [2] |
Target |
Action inhibitors |
Mechanism 3Cpro inhibitors(3C Protease inhibitors), PB2 inhibitors(polymerase basic protein 2 (PB2) inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC15H12O8 |
InChIKeyKJXSIXMJHKAJOD-LSDHHAIUSA-N |
CAS Registry27200-12-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Phase 2 | Mexico | 30 Oct 2019 | |
| Alcohol-Related Disorders | Phase 1 | United States | 15 Sep 2024 | |
| Liver Diseases, Alcoholic | Phase 1 | United States | 15 Sep 2024 | |
| Enterovirus Infections | Preclinical | China | 10 Jul 2025 | |
| Fibrosis, Liver | Preclinical | China | 01 Jan 2025 | |
| Influenza, Human | Preclinical | China | 01 Jul 2020 |





